Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Melanoma HELP
Based on 34,116 articles published since 2008
|||| 19 

These are the 34116 published articles about Melanoma that originated from Worldwide during 2008-2019.
 
+ Citations + Abstracts
Pages: 1 · 2 · 3 · 4 · 5 · 6 · 7 · 8 · 9 · 10 · 11 · 12 · 13 · 14 · 15 · 16 · 17 · 18 · 19 · 20
426 Editorial Ultraviolet a light: potential underlying causes of melanoma. 2010

Tang, Moon-Shong. · ·Future Oncol · Pubmed #21062150.

ABSTRACT: -- No abstract --

427 Editorial Paving the way to the cure of melanoma. 2010

Mouawad, Roger / Spano, Jean-Philippe / Khayat, David. · ·Melanoma Res · Pubmed #21045619.

ABSTRACT: -- No abstract --

428 Editorial MITF--past, present and future. 2010

Ronai, Ze'ev. · ·Pigment Cell Melanoma Res · Pubmed #20973928.

ABSTRACT: -- No abstract --

429 Editorial [Why indoor tanning must be taxed? A proposal from La Sécurité Solaire, WHO collaborating centre]. 2010

Boniol, Mathieu / Césarini, Pierre / Chignol, Marie-Christine / Césarini, Jean-Pierre / Doré, Jean-François. · ·Presse Med · Pubmed #20970955.

ABSTRACT: -- No abstract --

430 Editorial ISET device: a useful tool to answer some questions about the biologic behavior of melanocytic nevus cells. 2010

Descamps, Vincent / Basset-Seguin, Nicole / Soufir, Nadem. · ·Arch Dermatol · Pubmed #20956651.

ABSTRACT: -- No abstract --

431 Editorial The amazin' mets. 2010

McCalmont, Timothy H. · ·J Cutan Pathol · Pubmed #20950362.

ABSTRACT: -- No abstract --

432 Editorial Hope in translation. 2010

Anonymous4890673. · ·Nature · Pubmed #20881968.

ABSTRACT: -- No abstract --

433 Editorial Flipping or scrolling. 2010

Ronai, Ze'ev. · ·Pigment Cell Melanoma Res · Pubmed #20840118.

ABSTRACT: -- No abstract --

434 Editorial Treating cancer by targeting the immune system. 2010

Hwu, Patrick. · ·N Engl J Med · Pubmed #20818880.

ABSTRACT: -- No abstract --

435 Editorial Melanoma--an unlikely poster child for personalized cancer therapy. 2010

Smalley, Keiran S M / Sondak, Vernon K. · ·N Engl J Med · Pubmed #20818849.

ABSTRACT: -- No abstract --

436 Editorial Gene transfer by electrical fields. 2010

Rols, Marie-Pierre. · ·Curr Gene Ther · Pubmed #20718698.

ABSTRACT: -- No abstract --

437 Editorial The ups and downs of transcription factors in melanoma. 2010

Santiago-Walker, Ademi / Herlyn, Meenhard. · ·J Natl Cancer Inst · Pubmed #20660367.

ABSTRACT: -- No abstract --

438 Editorial The magic tool. 2010

McCalmont, Timothy H. · ·J Cutan Pathol · Pubmed #20653824.

ABSTRACT: -- No abstract --

439 Editorial Cut it out. 2010

McCalmont, Timothy H. · ·J Cutan Pathol · Pubmed #20642634.

ABSTRACT: -- No abstract --

440 Editorial Lighting the way to better health: vitamin D. 2010

Anonymous230666. · ·Lancet · Pubmed #20638551.

ABSTRACT: -- No abstract --

441 Editorial Of patches, blotches, speckles and stripes. 2010

Arnheiter, Heinz. · ·Pigment Cell Melanoma Res · Pubmed #20636990.

ABSTRACT: -- No abstract --

442 Editorial Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032. 2010

Rubinstein, Jill C / Sznol, Mario / Pavlick, Anna C / Ariyan, Stephan / Cheng, Elaine / Bacchiocchi, Antonella / Kluger, Harriet M / Narayan, Deepak / Halaban, Ruth. ·Department of Dermatology, Yale University School of Medicine, New Haven, CT 06520, USA. ·J Transl Med · Pubmed #20630094.

ABSTRACT: Activating mutations in BRAF kinase are common in melanomas. Clinical trials with PLX4032, the mutant-BRAF inhibitor, show promising preliminary results in patients selected for the presence of V600E mutation. However, activating V600K mutation is the other most common mutation, yet patients with this variant are currently excluded from the PLX4032 trials. Here we present evidence that a patient bearing the BRAF V600K mutation responded remarkably to PLX4032, suggesting that clinical trials should include all patients with activating BRAF V600E/K mutations.

443 Editorial Up in smoke. 2010

McCalmont, Timothy H. · ·J Cutan Pathol · Pubmed #20602664.

ABSTRACT: -- No abstract --

444 Editorial Animis opibusque parati. 2010

Ronai, Ze'ev. · ·Pigment Cell Melanoma Res · Pubmed #20518861.

ABSTRACT: -- No abstract --

445 Editorial Refinements of surgical technique in oncologic surgery. 2010

Karakousis, Constantine P. · ·J Surg Oncol · Pubmed #20512939.

ABSTRACT: -- No abstract --

446 Editorial A Festschrift for Martin C. Mihm, Jr. 2010

Murphy, George F. · ·J Cutan Pathol · Pubmed #20482668.

ABSTRACT: -- No abstract --

447 Editorial Is GP-led follow-up feasible? 2010

Francken, A B / Hoekstra-Weebers, J W / Hoekstra, H J. · ·Br J Cancer · Pubmed #20461088.

ABSTRACT: -- No abstract --

448 Editorial Melanoma susceptibility genes. 2010

Newton-Bishop, Julia / Gruis, Nelleke. · ·Melanoma Res · Pubmed #20442621.

ABSTRACT: -- No abstract --

449 Editorial Melanoma: a model for testing new agents in combination therapies. 2010

Ascierto, Paolo A / Streicher, Howard Z / Sznol, Mario. ·Unit of Medical Oncology and Innovative Therapy, National Tumor Institute, Naples, Italy. paolo.ascierto@gmail.com ·J Transl Med · Pubmed #20406483.

ABSTRACT: Treatment for both early and advanced melanoma has changed little since the introduction of interferon and IL-2 in the early 1990s. Recent data from trials testing targeted agents or immune modulators suggest the promise of new strategies to treat patients with advanced melanoma. These include a new generation of B-RAF inhibitors with greater selectivity for the mutant protein, c-Kit inhibitors, anti-angiogenesis agents, the immune modulators anti-CTLA4, anti-PD-1, and anti-CD40, and adoptive cellular therapies. The high success rate of mutant B-RAF and c-Kit inhibitors relies on the selection of patients with corresponding mutations. However, although response rates with small molecule inhibitors are high, most are not durable. Moreover, for a large subset of patients, reliable predictive biomarkers especially for immunologic modulators have not yet been identified. Progress may also depend on identifying additional molecular targets, which in turn depends upon a better understanding of the mechanisms leading to response or resistance. More challenging but equally important will be understanding how to optimize the treatment of individual patients using these active agents sequentially or in combination with each other, with other experimental treatment, or with traditional anticancer modalities such as chemotherapy, radiation, or surgery. Compared to the standard approach of developing new single agents for licensing in advanced disease, the identification and validation of patient specific and multi-modality treatments will require increased involvement by several stakeholders in designing trials aimed at identifying, even in early stages of drug development, the most effective way to use molecularly guided approaches to treat tumors as they evolve over time.

450 Editorial Dermoscopy between the lines. 2010

Jellinek, Nathaniel J. · ·Arch Dermatol · Pubmed #20404235.

ABSTRACT: -- No abstract --

Back · Next